Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Second neoplasms in adult patients submitted to haematopoietic stem cell transpl...
Journal Information
Vol. 150. Issue 11.
Pages 421-427 (June 2018)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 150. Issue 11.
Pages 421-427 (June 2018)
Original article
DOI: 10.1016/j.medcle.2018.03.003
Second neoplasms in adult patients submitted to haematopoietic stem cell transplantation
Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos
Visits
...
Anna Torrent
Corresponding author
atorrent@iconcologia.net

Corresponding author.
, Christelle Ferrá, Mireia Morgades, María-José Jiménez, Juan-Manuel Sancho, Susana Vives, Montserrat Batlle, Miriam Moreno, Blanca Xicoy, Albert Oriol, Gladys Ibarra, Josep-Maria Ribera
Servicio de Hematología Clínica, Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (3)
Table 1. Clinical characteristics and variables related to the transplantation of hematopoietic stem cells in the global series and in patients with a second neoplasm or without it.
Table 2. Characteristics of the second neoplasms in the global series and according to the type of hematopoietic stem cell transplant.
Table 3. Analysis of risk factors for the development of the second neoplasm.
Show moreShow less
Abstract
Background and objective

Patients submitted to haematopoietic stem cell transplantation (HSCT) are at increased risk of late complications, such as second neoplasm (SN). The incidence and risk factors of SN in patients receiving HSCT at a single centre were analyzed.

Patients and methods

The follow-up of adult patients who received a first HSCT (autologous [auto-HSCT] or allogeneic [allo-HSCT]) between January 2000 and December 2015 was reviewed. We collected their demographic characteristics, the primary disease and type of HSCT, and analyzed the cumulative incidence of SN and their risk factors.

Results

Of 699 transplanted patients (auto-HSCT, n=451; allo-HSCT, n=248), 42 (6%) developed SN (17 haematological and 25 solid), 31 post-auto-HSCT and 11 post-allo-HSCT. Haematologic SN were more frequent after auto-HSCT than after allo-HSCT. The median time between HSCT and SN was 4.09 years [range 0.07–13.15], with no differences between auto-HSCT and allo-HSCT. The cumulative incidence of SN was 5% (95% CI 3–6) at 5 years, 7% (95% CI 5–10) at 10 years and 11% (95% CI 8–15) at 15 years, without differences according to the type of HSCT. Only the age over 40 years correlated with an increased risk of SN.

Conclusions

In this series, the incidence of post-HSCT SN was similar to that previously described. Patients submitted to an auto-HSCT showed a higher frequency of haematologic SN. A higher incidence of SN was detected in patients older than 40 at the time of HSCT.

Keywords:
Haematopoietic stem cell transplantation
Second neoplasms
Solid tumours
Haematologic neoplasms
Resumen
Fundamento y objetivo

Los receptores de un trasplante de progenitores hematopoyéticos (TPH) tienen un mayor riesgo de complicaciones tardías, como las segundas neoplasias (SN). Se analizó la incidencia de SN en pacientes receptores de un TPH en un centro.

Pacientes y métodos

Estudio retrospectivo de pacientes adultos receptores de un primer TPH (autogénico [auto-TPH] o alogénico [alo-TPH]) entre enero de 2000 y diciembre de 2015. Se recogieron sus características demográficas, la enfermedad de base y el tipo de TPH, y se analizó la incidencia acumulada de SN y sus factores de riesgo.

Resultados

De 699 pacientes receptores de un auto-TPH (n=451) o alo-TPH (n=248), 42 (6%) desarrollaron una SN (17 hematológicas y 25 sólidas), 31 postauto-TPH y 11 postalo-TPH. Se observó un mayor número de SN hematológicas tras auto-TPH que tras alo-TPH. La mediana de tiempo entre el TPH y la SN fue de 4,09 años [extremos 0,07-13,15], sin diferencias entre auto-TPH y alo-TPH. La incidencia acumulada de SN post-TPH fue de 5% (IC 95% 3-6) a 5 años, 7% (IC 95% 5-10) a 10 años y 11% (IC 95% 8-15) a 15 años, sin diferencias en función del tipo de TPH. Solo la edad superior a los 40 años se correlacionó con un mayor riesgo de SN.

Conclusiones

En esta serie, la incidencia de SN post-TPH fue similar a la descrita. Los receptores de un auto-TPH presentaron mayor frecuencia de SN hematológicas. Se detectó una mayor incidencia de SN en pacientes de más de 40 años en el momento del TPH.

Palabras clave:
Trasplante de progenitores hematopoyéticos
Segundas neoplasias
Tumores sólidos
Neoplasias hematológicas

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos